[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 10, 1968


JAMA. 1968;204(11):999-1000. doi:10.1001/jama.1968.03140240055018

Rapidly improving immunosuppressive techniques open doors to the possibility of transplanting nonvital organs for cure or amelioration of disease. At least two of these possibilities have now passed beyond the stage of speculation or contemplation to that of animal and even human experimentation.

Sise et al1 transplanted spleens from litter-mate donors into two hemophilic beagle dogs. Immediately after transplantation in one dog, and after two hours in the other, the transplants began to function, supplying sufficient antihemophilic factor (AHF) to maintain plasma levels to a maximum of 112% and 184% human standard, respectively. Radioactive gold scanning showed that both the grafted and the normal spleens were present on the 14th day in one dog. Since the spleen is a major potential source of AHF when exposed to a trophic factor in the plasma of patients with hemophilia, its successful transplantation in the dog will undoubtedly encourage future trials in